EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics provides shareholders with an update on current trading in light of the COVID-19 pandemic
EKF Diagnostics will announce its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.
EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.
Standard form for notification of major holdings.
EKF Diagnostics provides the following the trading update for the year ended 31 December 2019.
EKF Diagnostics provides shareholders with the following update on current trading and performance bonuses.
EKF Diagnostics announces that it has entered into a non-exclusive Preferred Partner Arrangement with Mount Sinai Innovation Partners.
EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2019.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2019 on Tuesday 10 September 2019.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides the following trading update.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.